The categorization of breast tumors based on hormone receptor and HER2 status and the use of antihormonal and HER2-targeted therapy, respectively, are among the first examples for molecular-based classification and personalized cancer treatment that made a significant difference in clinical outcomes. The widespread use of mammograms has lead to increased diagnosis of early stage disease, including ductal carcinoma in situ (DCIS), which also contributed to a decrease in mortality rates. The pie chart in the adjacent figure shows frequencies of various clinically relevant breast cancer subtypes, and the top table summarizes the prognoses of these subtypes. Systematic characterization of breast cancer genomes has identified somatic mutations in several key signaling pathways depicted in the adjacent figure. The top 21 genes with the most frequent nucleotide sequence changes are summarized in the middle table. The increased activities of these signaling pathways serve both as therapeutic targets and as biomarkers guiding the selection of patients who would most likely benefit from particular therapies. Current pathways and compounds used for rationally designed targeted therapy in breast cancer are listed in the bottom table.
Estrogen Receptor Alpha
The estrogen receptor alpha (ERα) nuclear hormone receptor, encoded by ESR1, is a ligand-dependent transcription factor. Upon estrogen binding, ERα directly and indirectly activates the expression of numerous genes. ERα's activity is modulated by coactivators, including NCOA3. Whereas ERα is expressed in only a small subset of cells in normal breast epithelium, where it plays an important role in breast development and differentiation, 65%-70% of breast tumors display high ERα levels and estrogen dependency for growth. Therefore, these ER + tumors respond to endocrine therapy. Several therapeutic approaches have been designed to modulate ER activity, including competitive antagonists, downregulators of ER protein levels, and inhibitors of the aromatase enzyme that produces estrogen.
HER2
HER2, encoded by the ERBB2 proto-oncogene, is a receptor tyrosine kinase (RTK) and a member of the epidermal growth factor receptor (EGFR) family. HER2 forms heterodimers with all three other members of the EGFR family, yielding different complexes with different kinase activities and physiologic functions. ERBB2 is amplified and overexpressed in ~20%-25% of breast carcinomas, leading to their dependency on HER2 signaling. The number of HER2-targeted therapies has increased significantly in recent years; these therapies include simple or drug-conjugated antibodies and small-molecule inhibitors of RTK activity specific for HER2 or broader for additional EGFR family members. These therapies have significantly improved disease-specific and overall survival of patients with HER2 + breast cancer.
PI3K, AKT, and PTEN
PIK3CA encodes the 110 kDa catalytic subunit of a class I phosphatidylinositol 3-kinase (PI3K). The 85 kDa regulatory subunit acts as an adaptor and mediates the activation of PI3K by RTKs and other kinases. PI3K phosphorylates phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol-3,4,5triphosphate (PIP3). PIP3 plays a key role in regulating the activity of signaling cascades involved in cell growth, survival, proliferation, metabolism, motility, and morphology by recruiting PH-domain-containing proteins, including AKT1 and PDPK1, to the cell membrane. A large fraction of human malignancies, including ~30% of breast carcinomas, have somatic mutations in PIK3CA leading to constitutive activation of the downstream signaling pathway. The activity of PI3K is antagonized by the PTEN tumor suppressor. PTEN is a dual-specificity phosphatase that dephosphorylates PIP3, leading to inhibition of AKT kinase activity, and can also antagonize the MAP kinase pathway via its protein phosphatase function. Germline mutations in PTEN play a role in Cowden disease and Bannayan-Zonana syndrome leading to increased cancer risk. Somatic inactivation of PTEN is common in a wide range of human cancers, including breast cancer. Approximately 50% of breast carcinomas have an activated PI3K/AKT pathway due to mutations in one of its components, making this kinase signaling cascade an attractive therapeutic target. Small-molecule inhibitors targeting PI3K, AKT, mTOR, or their combination are in various phases of clinical development.
MAP3K1, MAP2K4, and JNK1
MAP3K1 is a mitogen-activated protein kinase (MAPK) kinase kinase that regulates the ERK and JNK MAPK pathways, the NF-κB transcription factor, and the p300 transcriptional coactivator. MAP2K4 is another member of the MAPK-JNK signaling pathway functioning between MAP3K1 and JNK. Frequent somatic mutations in MAP3K1 and MAP2K4 have recently been reported in breast cancer, identifying MAPK-JNK signaling as a key pathway in breast cancer.
